NCT06483048 - MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Fallopian Tube CarcinosarcomaRecurrent Female Reproductive System CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian CarcinosarcomaRecurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Primary Peritoneal CarcinosarcomaRefractory Fallopian Tube CarcinomaRefractory Female Reproductive System CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL

Autologous MUC1-activated T-cells

Given IV

DRUG

Bendamustine

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood and possible ascites sample collection

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

85259

RECRUITING

Mayo Clinic in Arizona, Scottsdale